Eluminex, a Suzhou Startup, Closes $50 Million Round for Ophthalmic Drugs

Eluminex Biosciences, a Suzhou ophthalmic biotech startup, closed a $50 million Series A Financing from Lilly Asia Ventures, Hillhouse's GL Ventures and Quan Capital. The company will discover and develop first-in-class and/or best-in-class therapies that address unmet vision-threatening diseases for global markets. Further details were not disclosed. Eluminex's headquarters and R&D facility are located in Suzhou , its business center is in Shanghai , and a global clinical and registration center is planned for the San Francisco Bay Area. More details.... Share this with colleagues: // //